AstraZeneca said its partner Ionis’ antisense therapy Wainua (eplontersen) failed a pivotal Phase 3 trial in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The drug did not beat placebo on a composite endpoint that included cardiovascular death and recurrent cardiovascular events, dealing another blow to the increasingly competitive heart-disease gene-silencing category. Rival approaches from Alnylam and BridgeBio have benefited from the competitive opening created by the failure. The loss also follows the broader industry lesson that sustained transthyretin knockdown does not necessarily translate into clinical event reduction within the trial timeline. A separate report noted that stock reaction in both AstraZeneca and Ionis was negative in early trading following the topline results. Roche’s recent Huntington’s and AstraZeneca’s current ATTR-CM outcomes together show how quickly sentiment can turn when Phase 3 endpoints do not land. For biotech investors and pipeline operators, the event increases the premium on robust Phase 3 design that captures both biomarker effect and clinically meaningful endpoints in ATTR-CM populations.